AgomAb Therapeutics NV

We are a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. We have assembled an executive team with deep scientific and clinical development expertise and a track record of strong business leadership. Tim Knotnerus, our Chief Executive Officer, has extensive experience in corporate development and venture capital and previously held the position of Vice President of Corporate Development at AM-Pharma, where he and his team secured a $600.0 million option-to-buy deal with Pfizer. Philippe Wiesel, M.D., our Chief Medical Officer, served as Chief Medical Officer at Genkyotex where he led clinical development of several anti-inflammatory and anti-fibrotic compounds for various fibrotic disorders including liver, lung, and kidney fibrosis. Dr. Wiesel also previously led the late-stage development and marketing approval for Raptiva at EMD Serono. Pierre Kemula, our Chief Financial Officer, joined us in 2024 from CureVac, N.V., where he successfully contributed as Chief Financial Officer to the company’s initial public offering on Nasdaq and several follow-on offerings during his eight-year tenure. Andrea S ez, Ph.D., our Chief Development Officer, previously served as Chief Operating Officer and Chief Scientific Officer at Origo Biopharma, S.L., where both ontunisertib (AGMB-129) and AGMB-447 were discovered.